Andrew Guggenhime - Sep 19, 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
President and CFO
Signature
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Sep 19, 2022
Transactions value $
-$64,313
Form type
4
Date filed
9/21/2022, 06:05 PM
Previous filing
Sep 7, 2022
Next filing
Jan 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $16.6K +3.1K +8.26% $5.35 40.6K Sep 19, 2022 Direct
transaction PCVX Common Stock Sale -$68.2K -2.62K -6.45% $26.02 38K Sep 19, 2022 Direct F1, F2
transaction PCVX Common Stock Sale -$12.7K -477 -1.25% $26.52 37.5K Sep 19, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -3.1K -0.68% $0.00 455K Sep 19, 2022 Common Stock 3.1K $5.35 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.46 to $26.445. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $26.465 to $26.56. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.